Intra-Cellular Therapies (NASDAQ: ITCI) reported Q2 EPS of ($0.71), $0.08 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $223.45 thousand versus the consensus estimate of $20 thousand.

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.